JPH0132207B2 - - Google Patents
Info
- Publication number
- JPH0132207B2 JPH0132207B2 JP1921982A JP1921982A JPH0132207B2 JP H0132207 B2 JPH0132207 B2 JP H0132207B2 JP 1921982 A JP1921982 A JP 1921982A JP 1921982 A JP1921982 A JP 1921982A JP H0132207 B2 JPH0132207 B2 JP H0132207B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- glycyrrhizic acid
- berberine chloride
- poe
- castor oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 16
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 15
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 15
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 15
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 15
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 15
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 15
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 239000004359 castor oil Substances 0.000 claims description 11
- 235000019438 castor oil Nutrition 0.000 claims description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 11
- 239000002736 nonionic surfactant Substances 0.000 claims description 9
- -1 polyoxyethylene Polymers 0.000 claims description 9
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 238000009835 boiling Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 3
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Description
本発明は、グリチルリチン酸と塩化ベルベリン
を含有する透明な液状医薬組成物に関する。
本発明者らは、グリチルリチン酸と塩化ベルベ
リンを組合せて配合し、より優れた薬効を有する
液状医薬組成物を開発すべく研究をおこなつた。
しかし、単にこの二成分を混合し、水溶液とした
場合、グリチルリチン酸と塩化ベルベリンは酸塩
基反応を惹起して不溶性のコンプレツクス（グリ
チルリチン酸１モルと塩化ベルベリン２モル）を
形成して沈殿を生じ、透明な液とすることは不可
能である。そして、生じたコンプレツクスが容器
に付着、沈殿する結果、均一溶液とすることが
困難になる、容器の出口がつまる、処方量と
製剤中の含有量に差が生じて目的とする効果が奏
されない等の欠点が生じていた。
この欠点を解決するため、生じたコンプレツク
スを去する方法及び界面活性剤により可溶化せ
しめる方法が試みられたが、前者の方法では、
過後の液中にも再度コンプレツクスの沈殿が生
じること及び前記の欠点を解消できないという
問題が、後者においては、長期間保存しているう
ちに沈殿が生ずるという問題があり、いずれも満
足のゆくものではなかつた。
そこで、本発明者らは更にグリチルリチン酸と
塩化ベルベリンを可溶化し、長期間安定で透明な
液状医薬組成物を得るべく鋭意検討していたとこ
ろ、ポリオキシエチレン硬化ヒマシ油誘導体及び
ポリエチレングリコール脂肪酸エステルより選ば
れた非イオン性界面活性剤とトコフエロールエス
テル類を可溶化剤として添加、配合すれば上記目
的が達成されることを見出し、本発明を完成し
た。
すなわち、本発明は次の４成分、
(A) グリチルリチン酸、
(B) 塩化ベルベリン、
(C) ポリオキシエチレン硬化ヒマシ油誘導体及び
ポリエチレングリコール脂肪酸エステルより選
ばれた非イオン性界面活性剤並びに
(D) トコフエロールエステル類
を含有する液状医薬組成物を提供するものであ
る。
本発明の(A)成分のグリチルリチン酸は通常医薬
組成物中0.01〜1.5重量％（以下単に％で示す）、
好ましくは0.05〜1.0％配合される。また(B)成分
の塩化ベルベリンは通常0.01〜1.5％、好ましく
は0.05〜1.0％配合される。
本発明で使用される(C)成分の非イオン性界面活
性剤としては、例えば、POE（40）モノステアレ
ート、POE（45）モノステアレート、POE（55）
モノステアレート等のポリエチレングリコール脂
肪酸エステル（商品名ニツコールMYS―40，
MYS―45，MYS―55）；POE（40）硬化ヒマシ
油、POE（50）硬化ヒマシ油、POE（60）硬化ヒ
マシ油、POE（100）硬化ヒマシ油等のポリオキ
シエチレン硬化ヒマシ油誘導体（商品名ニツコー
ルHCO―40，HCO―50，HCO―60，HCO―
100）等が挙げられ、これらは単独又は二種以上
組合せて医薬組成物中1.0〜10.0％、好ましくは
2.0〜8.0％配合される。更に(D)成分のトコフエロ
ールエステル類としては、酢酸トコフエロール、
ニコチン酸トコフエロール等が挙げられ、通常
0.1〜1.0％、好ましくは0.2〜0.8％配合される。
本発明の液状医薬組成物の製造は、常法に従
い、上記(A)〜(D)成分を水等の溶媒中撹拌しながら
混合し、必要に応じて水酸化ナトリウム等のアル
カリ性物質でPHを調整することによりおこなわれ
る。
この液状医薬組成物のPHは4.5〜10、特にPH５
〜８とするのが好ましい。
更にまた、本発明の医薬組成物には更に所望に
よりビタミン塩類、アミノ酸及びその塩類、液糖
及びシヨ糖並びに有機酸及びその塩類等の成分を
適宜配合することもできる。
斯くして得られた本発明の医薬組成物は、胃腸
薬、目薬、外皮用剤等として有用なものである。
次に実施例を挙げ本発明を説明する。
実施例 １
グリチルリチン酸0.5ｇ、塩化ベルベリン0.5
ｇ、非イオン性界面活性剤（POE（60）硬化ヒマ
シ油；ニツコールHCO―60）10ｇ及び酢酸トコ
フエロール0.5ｇを加え、加温しながらじゆうぶ
んかきまぜた後熱湯（滅菌精製水）を少量ずつ加
えながらかきまぜ、水酸化ナトリウム試液を加え
てPH６とし、全量250mlとして過する。得られ
た医薬組成物について、各条件での初期（製造１
日後）、６ケ月保存後及び12ケ月保存後のグリチ
ルリチン酸及び塩化ベルベリンの含有量並びに沈
殿物、浮遊物の発生を調べた。この結果は第１表
の通りである。
The present invention relates to a clear liquid pharmaceutical composition containing glycyrrhizic acid and berberine chloride. The present inventors conducted research to develop a liquid pharmaceutical composition containing glycyrrhizic acid and berberine chloride in combination and having better medicinal efficacy.
However, when these two components are simply mixed to form an aqueous solution, glycyrrhizic acid and berberine chloride cause an acid-base reaction to form an insoluble complex (1 mole of glycyrrhizic acid and 2 moles of berberine chloride), resulting in a precipitate. , it is impossible to form a transparent liquid. As a result, the resulting complex adheres to the container and precipitates, making it difficult to form a homogeneous solution, clogging the outlet of the container, and causing a difference between the prescribed amount and the content in the preparation, resulting in the desired effect not being achieved. There were drawbacks such as not being able to do so. In order to solve this drawback, attempts have been made to remove the resulting complex and to solubilize it with a surfactant, but the former method
In the case of the latter, there is a problem that precipitation of the complex occurs again in the solution after storage and that the above-mentioned drawbacks cannot be overcome, and in the latter case, there is a problem that precipitation occurs during long-term storage. It wasn't something. Therefore, the present inventors further solubilized glycyrrhizic acid and berberine chloride, and while conducting intensive studies to obtain a long-term stable and transparent liquid pharmaceutical composition, they found that polyoxyethylene hydrogenated castor oil derivatives and polyethylene glycol fatty acid esters The present invention has been completed based on the discovery that the above object can be achieved by adding and blending a selected nonionic surfactant and tocopherol esters as solubilizers. That is, the present invention comprises the following four components: (A) glycyrrhizic acid, (B) berberine chloride, (C) a nonionic surfactant selected from polyoxyethylene hydrogenated castor oil derivatives and polyethylene glycol fatty acid esters, and (D ) A liquid pharmaceutical composition containing tocopherol esters is provided. Glycyrrhizic acid, component (A) of the present invention, is usually 0.01 to 1.5% by weight (hereinafter simply expressed as %) in the pharmaceutical composition.
Preferably, it is blended in an amount of 0.05 to 1.0%. Further, component (B), berberine chloride, is usually blended in an amount of 0.01 to 1.5%, preferably 0.05 to 1.0%. Examples of the nonionic surfactant as component (C) used in the present invention include POE (40) monostearate, POE (45) monostearate, and POE (55) monostearate.
Polyethylene glycol fatty acid esters such as monostearate (product name: NITSUKOL MYS-40,
MYS-45, MYS-55); Polyoxyethylene hydrogenated castor oil derivatives such as POE (40) hydrogenated castor oil, POE (50) hydrogenated castor oil, POE (60) hydrogenated castor oil, POE (100) hydrogenated castor oil Product name NITSUKOL HCO-40, HCO-50, HCO-60, HCO-
100), etc., and these may be used alone or in combination of two or more in the pharmaceutical composition in an amount of 1.0 to 10.0%, preferably
Contains 2.0 to 8.0%. Furthermore, tocopherol esters as component (D) include tocopherol acetate,
Examples include tocopherol nicotinate, which is usually
It is blended in an amount of 0.1 to 1.0%, preferably 0.2 to 0.8%. The liquid pharmaceutical composition of the present invention is produced by mixing the above components (A) to (D) in a solvent such as water with stirring, and adjusting the pH with an alkaline substance such as sodium hydroxide as necessary. This is done by making adjustments. The pH of this liquid pharmaceutical composition is 4.5 to 10, especially PH5
It is preferable to set it to 8. Furthermore, the pharmaceutical composition of the present invention may further contain components such as vitamin salts, amino acids and their salts, liquid sugar and sucrose, and organic acids and their salts, as desired. The pharmaceutical composition of the present invention thus obtained is useful as a gastrointestinal medicine, an eye drop, a skin preparation, and the like. Next, the present invention will be explained with reference to Examples. Example 1 Glycyrrhizic acid 0.5g, berberine chloride 0.5g
g, add 10 g of nonionic surfactant (POE (60) hydrogenated castor oil; Nitsukol HCO-60) and 0.5 g of tocopherol acetate, stir well while heating, and then add boiling water (sterilized purified water) little by little. Stir while adding, adjust the pH to 6 by adding sodium hydroxide test solution, and filter the total volume to 250 ml. The obtained pharmaceutical composition was tested at the initial stage (manufacturing 1) under each condition.
After storage for 6 months and 12 months, the content of glycyrrhizic acid and berberine chloride as well as the occurrence of precipitates and suspended matter were examined. The results are shown in Table 1.
【表】【table】
【表】
実施例 ２
グリチルリチン酸0.5ｇ、塩化ベルベリン0.5
ｇ、非イオン性界面活性剤（POE（60）硬化ヒマ
シ油；ニツコールHCO―60）15ｇ及び酢酸トコ
フエロール２ｇを加え、加温しながらじゆうぶん
かきまぜた後、熱湯（滅菌精製水）を少量ずつ加
えながらかきまぜ、水酸化ナトリウム試液を加え
てPH８とし全量250mlとし過する。得られた医
薬組成物について、実施例１と同様に試験した結
果は第２表の通りである。[Table] Example 2 Glycyrrhizic acid 0.5g, Berberine chloride 0.5g
g, add 15 g of nonionic surfactant (POE (60) hydrogenated castor oil; Nitsukor HCO-60) and 2 g of tocopherol acetate, stir well while heating, and then add boiling water (sterilized purified water) little by little. Stir while adding and adjust the pH to 8 by adding sodium hydroxide test solution to bring the total volume to 250ml. The obtained pharmaceutical composition was tested in the same manner as in Example 1, and the results are shown in Table 2.
【表】
実施例 ３
グリチルリチン酸0.5ｇ、塩化ベルベリン0.5
ｇ、非イオン性界面活性剤（POE（40）モノステ
アレート；ニツコールMYS―40）20ｇ及び酢酸
トコフエロール2.0ｇを加え、加温しながらじゆ
うぶんかきまぜた後、熱湯（滅菌精製水）を少量
ずつ加えながらかきまぜ、水酸化ナトリウム試液
を加えてPH６とし、全量250mlとして過する。
得られた医薬組成物について、実施例１と同様に
試験した結果は、第３表の通りである。[Table] Example 3 Glycyrrhizic acid 0.5g, Berberine chloride 0.5
g, add 20 g of nonionic surfactant (POE (40) monostearate; Nitsukor MYS-40) and 2.0 g of tocopherol acetate, stir well while heating, and then add a small amount of boiling water (sterilized purified water). Stir while adding at a time, adjust the pH to 6 by adding sodium hydroxide test solution, and filter the total volume to 250 ml.
The obtained pharmaceutical composition was tested in the same manner as in Example 1, and the results are shown in Table 3.
【表】
実施例 ４
グリチルリチン酸0.5ｇ、塩化ベルベリン0.5
ｇ、非イオン性界面活性剤（POE（40）モノステ
アレート；ニツコールMYS―40）15ｇ及びニコ
チン酸トコフエロール1.5ｇを加え、加温しなが
らじゆうぶんかきまぜた後、熱湯（滅菌精製水）
を少量ずつ加えながらかきまぜ、水酸化ナトリウ
ム試液を加えてPH８とし、全量250mlとして過
する。得られた医薬組成物について、実施例１と
同様に試験した結果は第４表の通りである。[Table] Example 4 Glycyrrhizic acid 0.5g, Berberine chloride 0.5g
g, add 15 g of nonionic surfactant (POE (40) monostearate; Nitsukor MYS-40) and 1.5 g of tocopherol nicotinate, stir well while heating, and add boiling water (sterilized purified water).
Add it little by little while stirring, adjust the pH to 8 by adding sodium hydroxide test solution, and filter the total volume to 250ml. The obtained pharmaceutical composition was tested in the same manner as in Example 1, and the results are shown in Table 4.
【表】
比較例 １
グリチルリチン酸0.5ｇ、塩化ベルベリン0.5
ｇ、非イオン性界面活性剤（POE（60）硬化ヒマ
シ油；ニツコールHCO―60）20ｇを加え、加温
しながらじゆうぶんかきまぜた後、熱湯（滅菌精
製水）を少量ずつ加えながらかきまぜ、水酸化ナ
トリウム試液を加えてPH６とし、全量250mlとし
て過する。得られた医薬組成物について、実施
例１と同様に試験した結果は第５表の通りであ
る。[Table] Comparative example 1 Glycyrrhizic acid 0.5g, Berberine chloride 0.5g
g, add 20 g of nonionic surfactant (POE (60) hydrogenated castor oil; Nitsukor HCO-60), stir gently while heating, and then stir while adding boiling water (sterilized purified water) little by little. Add sodium hydroxide test solution to adjust the pH to 6, and filter the total volume to 250 ml. The obtained pharmaceutical composition was tested in the same manner as in Example 1, and the results are shown in Table 5.
【表】
第５表より明らかな如く、トコフエロールエス
テル類を配合しない場合、成分含量が低下し、し
かも長期間保存においては沈殿・浮遊物が生じ
る。
比較例 ２
グリチルリチン酸0.5ｇと塩化ベルベリン0.5ｇ
を250mlの水に溶解し、生じた沈殿・浮遊物を
過した後各成分量を分析して配合量に対する液
中の含有率を求めた。この結果は第６表の通りで
ある。[Table] As is clear from Table 5, when tocopherol esters are not blended, the component content decreases, and moreover, precipitates and suspended matter occur during long-term storage. Comparative example 2 Glycyrrhizic acid 0.5g and Berberine chloride 0.5g
was dissolved in 250 ml of water, the resulting precipitates and suspended matter were filtered out, and the amount of each component was analyzed to determine the content in the liquid relative to the blended amount. The results are shown in Table 6.
Claims (1)
ポリエチレングリコール脂肪酸エステルより選
ばれた非イオン性界面活性剤並びに (D) トコフエロールエステル類 を含有する液状医薬組成物。 ２ (C)成分の含有量が1.0〜10.0重量％、(D)成分
の含有量が0.1〜1.0重量％である特許請求の範囲
第１項記載の液状医薬組成物。 ３ PHが4.5〜10である特許請求の範囲第１項又
は第２項記載の液状医薬組成物。[Scope of Claims] 1. A nonionic surfactant selected from the following four components: (A) glycyrrhizic acid, (B) berberine chloride, (C) a polyoxyethylene hydrogenated castor oil derivative and a polyethylene glycol fatty acid ester, and (D) A liquid pharmaceutical composition containing tocopherol esters. 2. The liquid pharmaceutical composition according to claim 1, wherein the content of component (C) is 1.0 to 10.0% by weight, and the content of component (D) is 0.1 to 1.0% by weight. 3. The liquid pharmaceutical composition according to claim 1 or 2, which has a pH of 4.5 to 10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1921982A JPS58140014A (en) | 1982-02-09 | 1982-02-09 | Transparent liquid medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1921982A JPS58140014A (en) | 1982-02-09 | 1982-02-09 | Transparent liquid medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58140014A JPS58140014A (en) | 1983-08-19 |
| JPH0132207B2 true JPH0132207B2 (en) | 1989-06-29 |
Family
ID=11993249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1921982A Granted JPS58140014A (en) | 1982-02-09 | 1982-02-09 | Transparent liquid medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58140014A (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0647536B2 (en) * | 1985-12-24 | 1994-06-22 | ライオン株式会社 | Liquid containing tocopherols |
| JP2536786B2 (en) * | 1989-05-29 | 1996-09-18 | ゼリア新薬工業株式会社 | Stable eye drops |
| US6248309B1 (en) | 1997-04-04 | 2001-06-19 | Optiva Corporation | Gums containing antimicrobial agents |
| US5939050A (en) * | 1997-04-04 | 1999-08-17 | Optiva Corp. | Antimicrobial compositions |
| JP4753448B2 (en) * | 1999-08-10 | 2011-08-24 | ライオン株式会社 | Retinol palmitate, method for stabilizing retinol and aqueous vitamins |
| JP2004231600A (en) * | 2003-01-31 | 2004-08-19 | Takemitsu Ishigaki | Skin care preparation for external use |
| CN106074676B (en) * | 2016-06-14 | 2019-05-24 | 北京大学 | It is a kind of for treating the pharmaceutical composition of type-2 diabetes mellitus and its complication |
| JP7014078B2 (en) * | 2018-07-25 | 2022-02-01 | ライオン株式会社 | Ophthalmic composition and precipitation suppression method |
-
1982
- 1982-02-09 JP JP1921982A patent/JPS58140014A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58140014A (en) | 1983-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0178436B1 (en) | Soft gelatine capsules containing ibuprofen and process for their preparation | |
| US4751241A (en) | Pharmaceutical composition of cyclandelate having a high degree of bioavailability | |
| DE69929313T2 (en) | METHOD AND COMPOSITIONS FOR THE ADMINISTRATION OF TAXANES | |
| EP0325244B1 (en) | Aqueous solution of fat-soluble substance | |
| DE19543271B4 (en) | Oral pharmaceutical preparation | |
| SK85790A3 (en) | Associates of deprotonated hyaluronic acid, a method for the preparation thereof, pharmaceutical and cosmetic composition containing same | |
| DE60126433T2 (en) | PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS | |
| IE911901A1 (en) | Self-emulsifying glasses | |
| JPH07116029B2 (en) | Tranilast aqueous solution formulation | |
| EP2228054A1 (en) | Riluzole aqueous suspensions | |
| JPH0132207B2 (en) | ||
| JP3523260B2 (en) | Fenbendazole formulation | |
| JPH0525037A (en) | Oral administrative enzyme sensitive enteric coating | |
| IL257796A (en) | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same | |
| JPH05255126A (en) | Bitter taste-reducing composition | |
| CN110339165A (en) | A kind of Dexibuprofen fat emulsion injection and preparation method thereof | |
| CN105640956A (en) | Antiseptic-free compound codeine phosphate oral liquid and preparing method thereof | |
| US5783585A (en) | Solid bulk compositions containing quinolone carboxylic acids or naphthyridine carboxylic acids in free base form | |
| JPH0242020A (en) | Danazol composition | |
| JPH0283323A (en) | Stable aqueous solution of riboflavin butyrate | |
| EP3297677B1 (en) | Liquid pharmaceutical formulations of tetraiodothyronine | |
| KR0129787B1 (en) | Solubilization method of cold drugs centering ibuprofen | |
| JPS59110655A (en) | Manufacture of p-butoxyphenylacetylhydroxamic acid | |
| DE69819203T2 (en) | DRINKING MEDICINAL PRODUCT | |
| JPH01221312A (en) | Oral liquid containing fat-soluble substance |